BioCentury
ARTICLE | Emerging Company Profile

Preventing accumulation

How InFlectis aims to slow down translation of misfolded proteins

May 11, 2015 7:00 AM UTC

InFlectis BioScience S.A.S. is developing preclinical small molecules for Orphan diseases to slow production of misfolded proteins whose accumulation leads to disease. The goal is to turn up one of the three components of the unfolded protein response so that the other two components will be more effective.

The unfolded protein response is a normal response to cellular stress caused when unfolded or misfolded proteins accumulate in the endoplasmic reticulum. The response consists of three pathways: one that slows down protein synthesis, one that up-regulates chaperones that facilitate protein folding, and one that up-regulates proteases to degrade misfolded proteins...